期刊文献+

术前应用替罗非班对中、高危急性非ST段抬高型心肌梗死行急诊PCI术患者的临床研究 被引量:7

下载PDF
导出
摘要 目的:观察术前应用替罗非班在中、高危急性非ST段抬高型心肌梗死(NSTEMI)行急诊经皮冠状动脉介入治疗(PCI)患者,对术中无复流和住院期间主要不良心血管事件(MACE)及出血并发症的影响。方法:60例中、高危NSTEMI拟行急诊PCI的患者,随机分为替罗非班组和对照组,观察两组患者PCI术中无复流的发生率,住院期间MACE事件的发生率及出血并发症发生情况。结果:术中无复流的发生率应用替罗非班组明显低于对照组(替罗非班组6.5%比对照组27.6%,P?0.05),住院期间MACE事件的发生率应用替罗非班组与对照组没有明显差异,两组均未发生大量出血并发症。结论:术前应用替罗非班对中、高危急性非ST段抬高型心肌梗死行急诊PCI患者能减少术中无复流的发生率,安全性好。
出处 《陕西医学杂志》 CAS 2012年第8期962-964,共3页 Shaanxi Medical Journal
  • 相关文献

参考文献7

  • 1Fox KA,Poole-Wilson PA,Henderson RA,et al.Inter-ventional versus conservative treatment for patients withunstable angina or non-ST-segment elevation myocardialinfarction:the British Heart Foundation RITA 3random-ised trial[J].Lancet,2002,360(9335):743-751.
  • 2Brounwald E,Antman EM,Beasley JW,et al.ACC/AHA 2002guideline update for the management of pa-tients with unstable angina or non-ST-segment elevationmyocardial infarction:summary article:a report of theAmerican College of Cardiology/American Heart Associ-ation Task Force on Practice Guidelines[J].Circulation,2002,106:1893-1900.
  • 3Antman EM,Cohen M,Bernink PJ,et al.The TIMI riskscore for unstable angina/non-ST elevation MI:a methodfor prognostication and therapeutic decision making[J].JAMA,2000,284:835-842.
  • 4陈桂英,李为民.无复流现象及防治策略[M].李为民,霍勇,吕树铮.冠心病介入治疗策略与技巧.北京:人民卫生出版社,2007:57-69.
  • 5James C.Bleeding complications of glycoproteinⅡb∕Ⅲa receptor inhibitors[J].Am Heart J,1999,138:S287-294.
  • 6Martinez-rios MA,Rosas M,Gonzalez H,et al.Compar-ison of reperfusion regimens with or without tirofiban inST elevation acute myocardial infarction[J].Am J Cardi-ol,2004,93(3):280-287.
  • 7怯红晓,董平栓,杨旭明,王绍欣,杨喜山,李志娟,朱继红,王红雷,汪砚雨,王可,赵玉伟,闫鹏.替罗非班在老年非ST段抬高急性冠脉综合征介入治疗中的干预研究[J].陕西医学杂志,2009,38(4):464-466. 被引量:1

二级参考文献9

  • 1叶飞,陈绍良,朱中生,张俊杰,林松,周陵,刘玲玲,阚静,段宝祥.老年高危急性冠状动脉综合征患者介入术中应用替罗非班的有效性和安全性[J].中国介入心脏病学杂志,2007,15(2):93-95. 被引量:16
  • 2Bovill EG, Terrin ML , Stump DC , et al. for the TIMI investigators. Hemorrhagic events during therapy with reeombinan tissue typeplasminogen activator , heparin and aspirin for acute myrocardial infaretion. Ann Intern Med , 1991 ,115:256-265.
  • 3The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein II b III a receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Eng Med , 1998 , 338:1488-1497.
  • 4Egbertson MS, chang CT, Duggan ME, et al. Nonpeptide fibrinogen res-ceptor antagonist, optimization of a tyrosine-template as a mimic for Arg-Gy-Asp.. Med Chem, 1994, 37:2537-2551.
  • 5Lef kovittz J , Plow EF , Topol EJ . Platelet glycoprotein IIb/ IIIa receptor antagonist trial . Eur Heart J ,1999 ,I ( suppl E) :182 .
  • 6The RESTORE investigators. Effects of platelet glycoprotein II b/ III a blockade with irofiban on adverse cardiac events in patents with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation ,1997 ,96:1445-1453.
  • 7Henn V , Slupsky J R ,Grafe M ,et al. CD40ligand on activated platelets triggers an inflammatory reaction of endothelialcel-1s. Nature , 1998 , 391:591-594.
  • 8Graf D , Mullar S , Korthauer U ,et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur JImmunol , 1995 , 25: 1749-1754.
  • 9Andre P , Nannizzi Alaimo L , Prasad SK, et al. Platelet derived CD40L : the switch hitting player of cardiovascular disease. Circulation , 2002 , 106:896- 899.

同被引文献51

引证文献7

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部